MTPConnect is a not-for-profit organisation, established by the Australian Federal Government’s Industry Growth Initiative. MTPConnect’s aim is to accelerate the rate of growth of the medical technologies, biotechnologies and pharmaceuticals (MTP) sector to increase commercialisation, collaboration and establish Australia as an Asia-Pacific hub for MTP companies.
MTPConnect today announced its selection of industry training providers to deliver new programs addressing key skills gaps in the MTP sector workforce.
The skills gaps were identified in the first report of the comprehensive skills gap analyses being delivered under the Researcher Exchange and Development within Industry (REDI) initiative and the funding is provided from the first round of the REDI Contestable Program.
ARCS Australia will deliver training workshops in Melbourne and Sydney to address skills gaps relating to the strategic design of clinical trials to meet regulatory and payer needs for pharmaceuticals and medical devices.
SeerPharma will deliver a range of programs online and in capital cities to address skills gaps relating to quality management systems and protocols.
The new education and training programs will roll out nationally in April until late 2021.
MTPConnect Managing Director and CEO, Dr Dan Grant, says the REDI initiative is working to both identify key skills gaps and support new training programs to plug the gaps.
“Through our ‘root and branch’ skills gap analysis work we are developing a deep understanding of current and future skills gaps,” Dr Grant said.
“Now is the time to take action to fill the gaps, so with an eye on developing an industry-ready workforce that will power the next wave of innovation and growth, we’re supporting the development of bespoke education and training solutions through the REDI Contestable Program.
“This first round was highly competitive, and I congratulate ARCS and SeerPharma on their successful bids and welcome them as partners in our REDI program.
“These new training programs support areas of growth in our sector such as management of clinical trials and the translation and commercialisation of therapeutics and will help to ensure workforce skills are aligned to the current and future needs of the sector,” Dr Grant said.
SeerPharma Partner and Training Manager, David Spaulding, explained the company had been training and mentoring the medical technologies and pharmaceuticals industry on matters related to Quality Management and GMP compliance for over 30 years and the REDI partnership furthers their mission to “Advance Quality and GMP Best-Practices” for the industry.
“During this time, SeerPharma has seen the industry evolve using world-class research and development to deliver exceptional therapeutic products. In order to translate R&D into commercial product, a comprehensive understanding of quality systems is essential. We are excited to have been selected as a partner for REDI and look forward to delivering a suite of training programs from April around quality management systems that will benefit the MTP sector,” said Mr Spaulding.
The REDI initiative is funded through the Medical Research Future Fund operated by MTPConnect.
